Dermata rises on plans to begin enrollment for late-stage acne treatment study

Dermata Therapeutics

16/11/2023 14:04

** Shares of drug developer Dermata Therapeutics  DRMA.O 
rise 28.70% to 83 cents premarket
    ** Co to begin enrolling patients in Dec for a late-stage
trial of DMT310 which is being studied to treat
moderate-to-severe facial acne
    ** This comes after agreement with the U.S. FDA on the
protocols for its program which includes two late-stage trials
to study the efficacy, safety, and tolerability of DMT310
    ** Co is also developing the once-weekly, topical product
DMT310 for the treatment of multiple skin diseases
    ** Up to last close, stock down ~90% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))